NEW YORK, Aug. 5, 2009 (GLOBE NEWSWIRE) -- The Rosen Law Firm, P.A. announces that it is investigating potential securities claims against Repros Therapeutics, Inc. ("Repros") (Nasdaq:RPRX) pertaining to allegations that Repros misled investors about adverse events in the Company's clinical trials of Proellex which ultimately led the Company to suspend its clinical trials for Proellex, a drug it is developing for the treatment of chronic symptomatic uterine fibroids, anemia associated with this conduction, and endometriosis.
On August 3, 2009 the Company announced that it was suspending all further dosing of Proellex in their clinical trials as a result of serious adverse events. The August 3rd announcement disclosed that the adverse events were more frequent and more serious than the Company had previously reported. As a result of this adverse news, the Company's stock fell over 70%.
The Rosen Law Firm is evaluating the rights of Repros shareholders against Repros and certain of its officers and directors in connection with the Company's belated disclosures concerning its clinical trials. If you purchased Repros securities between January 1, 2009 and July 31, 2009, inclusive, and would like further information concerning your rights or want to join the proposed class action, please contact Laurence Rosen, Esq. or Phillip Kim, Esq. of The Rosen Law Firm toll free at 866-767-3653 or via e-mail at lrosen@rosenlegal.com, or pkim@rosenlegal.com or visit the firm's website at www.rosenlegal.com.
The Rosen Law Firm represents investors throughout the United States, concentrating its practice in securities class actions and shareholder derivative litigation.
Attorney Advertising. Prior results do not guarantee a similar outcome.